Vir Biotechnology (VIR) Operating Expenses (2018 - 2026)
Vir Biotechnology (VIR) posted Operating Expenses of $132.3 million for Q1 2026, up 18.1% sequentially from $112.0 million in Q4 2025, and down 7.24% YoY from $142.6 million in Q1 2025.
Vir Biotechnology (VIR) Operating Expenses (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Operating Expenses for 9 years, with the latest figure at $132.3 million in Q1 2026.
- Quarterly Operating Expenses fell 7.24% year-over-year to $132.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $537.6 million (down 19.46% YoY) and the FY2025 annual result came in at $547.9 million, down 17.16% from the prior year.
- Operating Expenses improved to $132.3 million in Q1 2026 per VIR's latest filing, from $112.0 million in the prior quarter.
- Over five years, Operating Expenses peaked at $233.7 million in Q3 2024 and troughed at $112.0 million in Q4 2025.
- A 5-year average of $170.3 million and a median of $173.7 million in 2025 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2024: Operating Expenses jumped 59.06% in 2022, then tumbled 33.86% in 2024.
- Over 5 years, Operating Expenses stood at $199.9 million in 2022, then declined by 22.06% to $155.8 million in 2023, then decreased by 16.87% to $129.5 million in 2024, then slipped by 13.54% to $112.0 million in 2025, then climbed by 18.1% to $132.3 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $132.3 million, $112.0 million, and $173.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 165.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 165.48 Mn |
| Mar 31, 2026 | 132.26 Mn |
| Dec 31, 2025 | 111.99 Mn |
| Sep 30, 2025 | 173.68 Mn |
| Jun 30, 2025 | 119.63 Mn |
| Mar 31, 2025 | 142.58 Mn |
| Dec 31, 2024 | 129.52 Mn |
| Sep 30, 2024 | 233.68 Mn |
| Jun 30, 2024 | 161.71 Mn |
| Mar 31, 2024 | 136.46 Mn |
| Dec 31, 2023 | 155.80 Mn |
| Sep 30, 2023 | 189.37 Mn |
| Jun 30, 2023 | 218.98 Mn |
| Mar 31, 2023 | 206.33 Mn |
| Dec 31, 2022 | 199.91 Mn |
| Sep 30, 2022 | 179.59 Mn |
| Jun 30, 2022 | 184.59 Mn |
| Mar 31, 2022 | 218.63 Mn |
| Dec 31, 2021 | 241.00 Mn |
| Sep 30, 2021 | 157.00 Mn |